Evaluation of treatment plan by three-period pulses of high-dose dexamethasone among patients with primary immune thrombocytopenia on platelet count response and adverse events: A randomized Clinical trial

BACKGROUND: Primary immune thrombocytopenia (ITP) decreases platelet count as well as increases the risk of bleeding due to platelet destruction in an autoimmune disorder. For many years, prednisone (PDN) has been the standard first-line treatment in ITP practical guidelines. The current randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadeghi, Alireza, Hosseini, Seyyideh Forough, Jouzdani, Saeid Rezaei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698390/
https://www.ncbi.nlm.nih.gov/pubmed/33273933
http://dx.doi.org/10.4103/jrms.JRMS_257_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698390/
https://www.ncbi.nlm.nih.gov/pubmed/33273933
http://dx.doi.org/10.4103/jrms.JRMS_257_19

Ejemplares similares